OBJECTIVES: To conduct an economic evaluation comparing, ferinject (Ferric Carboxymaltose) with Venofer (iron sucrose), iron sucrose similars (ISS-generic forms of iron sucrose) and Cosmofer (low molecular weight-LMW iron dextran) in the management of anaemia patients in Greece METHODS: A cost-minimization analysis, from National Health System (NHS) perspective, was conducted since there are no clear data indicating that one of these regimens is superior to the others in terms of efficacy. Because iron could be administered either to inpatients (i.e., surgical patients or patients hospitalized due to a disease related to chronic or acute blood loss) or to outpatients (i.e. non-dialysis chronic kidney disease patients etc), the economic evaluation was undertaken for these two large categories of patients, separately. Total cost related to each treatment includes the cost of drugs, the cost of disposables for each infusion, the monitoring cost during infusion (salaries of personnel), the cost for management of adverse events, the cost of visits, the productivity loss, and the travelling cost of patients. A supplementary budget impact analysis was also conducted. RESULTS: The mean total (direct) cost of therapy with Ferric Carboxymaltose was €216.32, in the iron sucrose arm the cost was €296.34, in the LMW iron dextran arm was €251.12, while in the ISS the cost was estimated at €324.47 for inpatients. In the case of outpatients the cost of ferric carboxymaltose was €152.66, the cost of iron sucrose was €285.10, the cost of LMW iron dextran was €459.88 and the cost of ISS was estimated at €313.13. Various sensitivity analyses showed that the main results were robust, reaching a statistical significant difference in 95% level of significance. CONCLUSIONS: Ferric Carboxymaltose represents a cost-saving option compared with other alternative therapies used in the management of anaemia in the National Health Service of Greece.